
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical Ltd has recently secured a radioactive material license from the New Hampshire Bureau of Public Health Protection, marking a significant operational milestone as it prepares to start U.S. manufacturing of its Alpha DaRT technology in 2026. The company enjoys a strong cash position, which supports its ongoing development efforts in the oncology therapeutics space targeting solid tumors. Despite reporting a net loss of $11.7 million, the strong prospects for Alpha DaRT to address unmet needs in cancer treatment contribute to a positive outlook for the company’s stock.
Bears say
Alpha Tau Medical recorded a net loss of $11.7 million in the third quarter of 2025, highlighting ongoing financial challenges for the company. Significant risks that may adversely impact its future performance include the potential failure of its Alpha DaRT technology in clinical trials, difficulties in securing regulatory approval within the U.S., and obstacles in achieving commercial success due to factors such as market size and competition. Additionally, the company faces potential dilution risks, which could further undermine investor confidence and stock performance.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares